Scinai Immunotherapeutics Ltd. (SCNI) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $309,769 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | IL | CEO | Amir Reichman |
| IPO Date | 2015-05-11 | CAGR | — |
| Employees | 45 | Website | www.scinai.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $264,688 | P/E | -0.02 | Forward P/E | — | PEG | — |
| P/S | 0.01 | P/B | — | P/CF | — | P/FCF | -0.01 |
| Sales | $1.42M | Sales 1Y | 35.48% | Sales 3Y | inf% | Sales 5Y | inf% |
| EPS | $-14.23 | EPS 1Y | -319866.67% | EPS 3Y | -102.82% | EPS 5Y | -101.83% |
| Sales QoQ | 84.98% | EPS QoQ | -960100% | Sales QoQ Avg | 12.95% | EPS QoQ Avg | -240041.67% |
| Gross Margin | -221.32% | Operating Margin | -573.87% | Profit Margin | -188.87% | ROCE | -54.49% |
| ROA | -15% | ROE | -30% | Altman Z Score | -11.29 | Piotroski Score | 3 |
| Current Ratio | 1.35 | Quick Ratio | 1.35 | Cash Ratio | 1.16 | Op. CF Ratio | -0.54 |
| Debt/Equity | 0.3 | Debt/Assets | 0.2 | Lt Debt/Equity | 0.27 | Lt Debt/Cap. | 0.02 |
| Intrst Cov. | -17.66 | Inventory Turnover | — | Asset Turnover | 0.08 | Receivables Turnover | 9.43 |
| Enterprise Value | $264,688 | P/E Ratio | -0.02 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 0.01 | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | -0.01 |
| EPS | $-14.23 | EPS Growth 1Y | -319866.67% |
| EPS Growth 3Y | -102.82% | EPS Growth 5Y | -101.83% |
| Revenue Growth 1Y | 35.48% | Gross Margin | -2.21% |
| Operating Margin | -5.74% | Profit Margin | -1.89% |
| ROE | -0.3% | ROA | -0.15% |
| ROCE | -0.54% | Current Ratio | 1.35 |
| Quick Ratio | 1.35 | Cash Ratio | 1.16 |
| Debt/Equity | 0.3 | Interest Coverage | -17.66 |
| Altman Z Score | -11.29 | Piotroski Score | 3 |
Scinai Immunotherapeutics Ltd. (SCNI) valuation & financials
Scinai Immunotherapeutics Ltd. (SCNI) has a market capitalization of $309,769 and trades at a price-to-earnings ratio of -0.0. It operates in the Healthcare sector (Biotechnology).
Scinai Immunotherapeutics Ltd.'s revenue grew +35.5% over the last year.
Scinai Immunotherapeutics Ltd.'s next earnings report is scheduled for August 20, 2026. Check the earnings calendar to see all companies reporting this week.
Scinai Immunotherapeutics Ltd. (SCNI) — frequently asked questions
When does Scinai Immunotherapeutics Ltd. (SCNI) report earnings next?
Scinai Immunotherapeutics Ltd. is expected to report earnings on August 20, 2026.
What is Scinai Immunotherapeutics Ltd.'s market cap?
Scinai Immunotherapeutics Ltd. (SCNI) has a market capitalization of $309,769.
What is SCNI's P/E ratio?
Scinai Immunotherapeutics Ltd. trades at a price-to-earnings ratio of -0.0, with trailing twelve-month EPS of $-14.23.
How fast is Scinai Immunotherapeutics Ltd. growing?
Scinai Immunotherapeutics Ltd.'s revenue grew +35.5% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)